NO333366B1 - Aktivert skum - Google Patents
Aktivert skum Download PDFInfo
- Publication number
- NO333366B1 NO333366B1 NO20062808A NO20062808A NO333366B1 NO 333366 B1 NO333366 B1 NO 333366B1 NO 20062808 A NO20062808 A NO 20062808A NO 20062808 A NO20062808 A NO 20062808A NO 333366 B1 NO333366 B1 NO 333366B1
- Authority
- NO
- Norway
- Prior art keywords
- foam
- activated
- activated foam
- cells
- prostate cancer
- Prior art date
Links
- 239000006260 foam Substances 0.000 title claims abstract description 79
- 229920003002 synthetic resin Polymers 0.000 claims abstract description 11
- 239000000057 synthetic resin Substances 0.000 claims abstract description 11
- 150000002291 germanium compounds Chemical class 0.000 claims abstract description 10
- 150000003755 zirconium compounds Chemical class 0.000 claims abstract description 9
- 229920003051 synthetic elastomer Polymers 0.000 claims abstract description 7
- 239000005061 synthetic rubber Substances 0.000 claims abstract description 7
- 244000043261 Hevea brasiliensis Species 0.000 claims abstract description 6
- 229920003052 natural elastomer Polymers 0.000 claims abstract description 6
- 229920001194 natural rubber Polymers 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims description 17
- 239000008177 pharmaceutical agent Substances 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 230000003217 anti-cancerogenic effect Effects 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000001647 drug administration Methods 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 55
- 206010060862 Prostate cancer Diseases 0.000 description 33
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- 201000011510 cancer Diseases 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 229920001971 elastomer Polymers 0.000 description 14
- 239000005060 rubber Substances 0.000 description 13
- 230000002411 adverse Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 108010077544 Chromatin Proteins 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 210000003483 chromatin Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 229910052732 germanium Inorganic materials 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 102000003964 Histone deacetylase Human genes 0.000 description 5
- 108090000353 Histone deacetylase Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 5
- 229920001084 poly(chloroprene) Polymers 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000004088 foaming agent Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- -1 polypropylene Polymers 0.000 description 4
- 238000004073 vulcanization Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 229910052726 zirconium Inorganic materials 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NBOCQTNZUPTTEI-UHFFFAOYSA-N 4-[4-(hydrazinesulfonyl)phenoxy]benzenesulfonohydrazide Chemical compound C1=CC(S(=O)(=O)NN)=CC=C1OC1=CC=C(S(=O)(=O)NN)C=C1 NBOCQTNZUPTTEI-UHFFFAOYSA-N 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 102100038023 DNA fragmentation factor subunit beta Human genes 0.000 description 2
- 102000015212 Fas Ligand Protein Human genes 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 2
- 101000950965 Homo sapiens DNA fragmentation factor subunit beta Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 206010071119 Hormone-dependent prostate cancer Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920000459 Nitrile rubber Polymers 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- SWEYNHYBJHPVJL-UHFFFAOYSA-N butanoic acid;sodium Chemical compound [Na].CCCC(O)=O SWEYNHYBJHPVJL-UHFFFAOYSA-N 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000002737 cell proliferation kit Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229920003049 isoprene rubber Polymers 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229910052845 zircon Inorganic materials 0.000 description 2
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 2
- VVXLFFIFNVKFBD-UHFFFAOYSA-N 4,4,4-trifluoro-1-phenylbutane-1,3-dione Chemical compound FC(F)(F)C(=O)CC(=O)C1=CC=CC=C1 VVXLFFIFNVKFBD-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229920001821 foam rubber Polymers 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229920002681 hypalon Polymers 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005160403 | 2005-04-29 | ||
| PCT/JP2005/008906 WO2006117881A1 (ja) | 2005-04-29 | 2005-05-16 | 活性発泡体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20062808L NO20062808L (no) | 2007-05-08 |
| NO333366B1 true NO333366B1 (no) | 2013-05-13 |
Family
ID=37307688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20062808A NO333366B1 (no) | 2005-04-29 | 2006-06-15 | Aktivert skum |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20070254034A1 (ja) |
| EP (1) | EP1902718B1 (ja) |
| JP (2) | JP5932194B2 (ja) |
| KR (1) | KR100871643B1 (ja) |
| CN (1) | CN100589795C (ja) |
| AU (1) | AU2005330574B8 (ja) |
| BR (1) | BRPI0510510B8 (ja) |
| CA (1) | CA2567807C (ja) |
| HK (1) | HK1111891A1 (ja) |
| MX (1) | MXPA06013339A (ja) |
| NO (1) | NO333366B1 (ja) |
| NZ (1) | NZ548087A (ja) |
| RU (1) | RU2343901C2 (ja) |
| TW (1) | TW200643072A (ja) |
| UA (1) | UA84762C2 (ja) |
| WO (1) | WO2006117881A1 (ja) |
| ZA (1) | ZA200605814B (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9344246B2 (en) | 2010-10-08 | 2016-05-17 | Qualcomm Incorporated | Reference signal configuration and relay downlink control channel |
| US9130725B2 (en) | 2010-11-02 | 2015-09-08 | Qualcomm Incorporated | Interaction of PDSCH resource mapping, CSI-RS, and muting |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1234039A (ja) * | 1968-02-22 | 1971-06-03 | ||
| JPS56141333A (en) * | 1980-04-08 | 1981-11-05 | Inoue Mtp Co Ltd | Synthetic resin foam having healthful action |
| US4890872A (en) * | 1986-10-08 | 1990-01-02 | Webcraft Technologies, Inc. | Flat paper sheet item for distributing a thin layer of material |
| JPH01182030A (ja) | 1988-01-14 | 1989-07-19 | Yuji Oku | 合成ゴム発泡体 |
| US6007817A (en) * | 1988-10-11 | 1999-12-28 | University Of Southern California | Vasopermeability enhancing immunoconjugates |
| JPH0347126A (ja) | 1989-02-03 | 1991-02-28 | Taisho Pharmaceut Co Ltd | 制癌剤 |
| US5051288A (en) | 1989-03-16 | 1991-09-24 | International Business Machines Corporation | Thin film magnetic recording disk comprising alternating layers of a CoNi or CoPt alloy and a non-magnetic spacer layer |
| JPH0341702A (ja) | 1989-07-10 | 1991-02-22 | Mitsubishi Electric Corp | 超電導コイル |
| JPH03107831A (ja) | 1989-09-21 | 1991-05-08 | Sony Corp | 撮像装置 |
| JP2873730B2 (ja) | 1990-08-01 | 1999-03-24 | 大日本除虫菊株式会社 | 表在癌および深部癌治療具 |
| JPH04187634A (ja) | 1990-11-21 | 1992-07-06 | Kyowa Hakko Kogyo Co Ltd | リポソーム製剤 |
| JPH065949A (ja) | 1992-06-19 | 1994-01-14 | Fujikura Ltd | 圧電体フィルムの製法 |
| JPH06321789A (ja) * | 1993-05-11 | 1994-11-22 | Ikuo Ogata | ゲルマニウム軟膏剤 |
| JPH0796045A (ja) | 1993-06-10 | 1995-04-11 | Sotaro Osato | 癌の遠赤外線温熱治療具 |
| JP3208252B2 (ja) | 1994-06-22 | 2001-09-10 | 大井電気株式会社 | 文字を数字に変換し表示する機能を有する選択呼出受信機 |
| KR960039576A (ko) | 1995-04-28 | 1996-11-25 | 이나바 세이우에몬 | 서보 모터용 인버터의 회생 저항 보호 방법 및 보호 장치 |
| TW407137B (en) * | 1996-10-21 | 2000-10-01 | Food Industry Res & Dev Inst | Process for separating organogermanium compounds and inorganogermanium compounds from a germanium-containing pharmaceutical plant or its processed products |
| JPH10245703A (ja) | 1997-02-28 | 1998-09-14 | Suzuki:Kk | 遠赤外線放射衣類 |
| JPH11116488A (ja) * | 1997-10-08 | 1999-04-27 | Toagosei Co Ltd | 制癌剤 |
| US6616925B1 (en) | 1998-04-02 | 2003-09-09 | I.D.M. Immuno-Designed Molecules | Combined preparation for the treatment of neoplasic diseases or of infectious diseases |
| WO1999051278A1 (en) | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | Inorganic material for radioactive drug delivery |
| JP4405602B2 (ja) * | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
| JPH11310537A (ja) | 1998-04-27 | 1999-11-09 | Toagosei Co Ltd | 温熱療法及び薬剤 |
| JP2000034228A (ja) | 1998-07-17 | 2000-02-02 | Mitsubishi Chemicals Corp | 頚椎捻挫治療剤 |
| RU2147222C1 (ru) | 1999-02-02 | 2000-04-10 | Матковская Татьяна Александровна | Средство для ухода за полостью рта |
| JP2003516441A (ja) | 1999-12-10 | 2003-05-13 | エクソンモービル・ケミカル・パテンツ・インク | プロピレンとジエンのコポリマーから形成された物品 |
| EP1166991B1 (en) * | 2000-06-22 | 2006-02-22 | Mitsui Chemicals, Inc. | Process, machine and composition for injection foaming |
| JP2002219182A (ja) | 2001-01-24 | 2002-08-06 | Tokyo Kaken Kk | 遠赤外線腫瘍治療具 |
| DK1523997T3 (en) * | 2001-02-08 | 2015-11-23 | Coloplast As | Foam dressings comprising antimicrobial silver |
| US6455610B1 (en) * | 2001-03-23 | 2002-09-24 | Milliken & Company | Antimicrobial pre-vulcanized rubber compositions |
| JP2003002826A (ja) * | 2001-06-20 | 2003-01-08 | Nippon Hanekku:Kk | マイナスイオン発生外用貼付剤 |
| JP2003082141A (ja) | 2001-09-13 | 2003-03-19 | Mitsubishi Chemicals Corp | 脂肪族ポリエステル系樹脂押出発泡体 |
| JP2003231638A (ja) * | 2002-02-04 | 2003-08-19 | Nihon Kankyo Science Co Ltd | 鼻用血行促進補助テープ |
| JP2003238398A (ja) * | 2002-02-08 | 2003-08-27 | Tenshindo Sanwa:Kk | 人体内不純物排出促進方法 |
| JP2003268143A (ja) | 2002-03-15 | 2003-09-25 | Mitsubishi Chemicals Corp | 発泡体製造用脂肪族ポリエステル系樹脂及び発泡体 |
| EP1501489A4 (en) * | 2002-04-15 | 2007-11-21 | Sloan Kettering Inst Cancer | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
| JP2003160774A (ja) * | 2002-10-23 | 2003-06-06 | Nisshin Giken Kk | 機能性貼布材 |
| JP2005002374A (ja) * | 2003-06-10 | 2005-01-06 | Toyo Shoji Kk | 健康増進具とその製造方法 |
| DK2238982T3 (da) * | 2003-06-27 | 2013-01-28 | Astellas Pharma Inc | Terapeutisk middel til blødt væv-sarcom |
| US7056773B2 (en) * | 2004-04-28 | 2006-06-06 | International Business Machines Corporation | Backgated FinFET having different oxide thicknesses |
| JP3107831U (ja) * | 2004-09-21 | 2005-02-17 | 株式会社イヴ | ネックウォーマ |
-
2005
- 2005-04-29 NZ NZ548087A patent/NZ548087A/en unknown
- 2005-05-16 AU AU2005330574A patent/AU2005330574B8/en active Active
- 2005-05-16 CA CA2567807A patent/CA2567807C/en active Active
- 2005-05-16 US US10/582,801 patent/US20070254034A1/en not_active Abandoned
- 2005-05-16 RU RU2006140873/15A patent/RU2343901C2/ru active
- 2005-05-16 KR KR1020067011826A patent/KR100871643B1/ko active IP Right Grant
- 2005-05-16 JP JP2006536494A patent/JP5932194B2/ja active Active
- 2005-05-16 WO PCT/JP2005/008906 patent/WO2006117881A1/ja not_active Application Discontinuation
- 2005-05-16 EP EP05739247A patent/EP1902718B1/en active Active
- 2005-05-16 BR BRPI0510510A patent/BRPI0510510B8/pt active IP Right Grant
- 2005-05-16 MX MXPA06013339A patent/MXPA06013339A/es active IP Right Grant
- 2005-05-16 UA UAA200612804A patent/UA84762C2/ru unknown
- 2005-05-16 CN CN200580001866A patent/CN100589795C/zh active Active
-
2006
- 2006-03-02 TW TW095107046A patent/TW200643072A/zh unknown
- 2006-06-15 NO NO20062808A patent/NO333366B1/no unknown
- 2006-07-14 ZA ZA200605814A patent/ZA200605814B/xx unknown
-
2008
- 2008-06-12 HK HK08106536.0A patent/HK1111891A1/xx unknown
-
2010
- 2010-08-12 US US12/855,089 patent/US9125819B2/en active Active
-
2011
- 2011-09-28 JP JP2011213138A patent/JP5977009B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bullamore et al. | Effect of age on calcium absorption | |
| Galper et al. | Diagnosis and management of mycosis fungoides | |
| Xu et al. | Physical activity and breast cancer prevention: possible role of immune mediators | |
| Reijmen et al. | Fractionated radiation severely reduces the number of CD8+ T cells and mature antigen presenting cells within lung tumors | |
| Murat Emsen et al. | Epidermodysplasia verruciformis: An early and unusual presentation | |
| Malvicini et al. | Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12 | |
| NO333366B1 (no) | Aktivert skum | |
| Yin et al. | Ferroptosis and cancer immunotherapy | |
| Dummer et al. | Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up | |
| Gamsiz et al. | Evaluation of mycosis fungoides management by total skin electron beam therapy with “translational technique” | |
| Hane et al. | Extraordinarily large, giant spider angioma in an alcoholic cirrhotic patient. | |
| Pandolfi et al. | Common variable immunodeficiency-new insight into the pathogenesis and the quest for a workable classification | |
| Meduri et al. | Corticosteroids in ARDS: a counterpoint | |
| Zhang et al. | Quaternary amines exert anti-myocardial ischemia effects via regulation of energy metabolism and oxygen free radicals in myocardial cells in acute myocardial infarction rats | |
| Catanoso et al. | Improved T-and B-Cell Neogenesis in Children with Acute Leukemia Given an Alpha-Beta T-Cell Depleted Haplo-HSCT Combined with the Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (Rivo-cel) | |
| Vaughan-Shaw et al. | Rectal Cancer genes down-regulated by Vitamin D (3,200 IU only helped some)–RCT Aug 2021 | |
| Tchernev | Global Dermatology: Learning from the Past but Still Learning from the Best? Open Access Maced J Med Sci. 2017 Jul 25; 5 (4): 399-402 | |
| Yaoqin et al. | The enhancement of Tween-80 on the antitumor effect of the hyperthermia 41 C in tumor-bearing mice | |
| Kawaguchi et al. | Correlation between Docetaxel-Induced Skin Toxicity and the use of Steroids and H2 Blockers: A Multi-Institution Survey | |
| Tamiya et al. | Prospective Study of Switch from Oral Medicine of Tramadolto Fentanyl Sticking Medicine in Thoracic Malignancy with the Pain | |
| Xiao et al. | Contribution of CCDC134, a Potential Cytokine, to CD8~+ T Cell Effector Functions in Cancer Immunotherapy | |
| Nomura et al. | Irsogladine Maleate Reduces the Incidence of Oral Mucositis in Patients Receiving Fluorouracil-Based Chemotherapy: A Pilot Study | |
| Monzen et al. | Radiotherapy for mucosa-associated lymphoid tissue lymphoma of the ocular adnexa | |
| Zilembo et al. | Hormonal-therapy in patients with stage-iv breast-cancer at diagnosis | |
| Wolf et al. | 76th Annual Meeting of the Swiss Society for Dermatology and Venereology |